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Abstract
Loss of the 3p21.3–encoded semaphorins, SEMA3B
and SEMA3F is implicated in lung cancer development.
Although both antagonize VEGF binding/response to
neuropilin (NRP) receptors, in lungcancer lines, SEMA3F
is predominantly expressed and preferentially utilizes
NRP2. In lung cancer patients, SEMA3F loss correlates
with advanced disease and increased VEGF binding
to tumor cells. In cell lines, VEGF enhances adhesion
and migration in an integrin-dependent manner, and
exogenous SEMA3F causes cells to round and lose extra-
cellular contacts. Using retroviral infections, we estab-
lished stable SEMA3F transfectants in two NSCLC cell
lines, NCI-H157 and NCI-H460. When orthotopically in-
jected into nude rats, both control lines caused lethal
tumors in all recipients. In contrast, all animals receiving
H157-SEMA3F cells, survived to 100 days, whereas all
H157 controls succumbed. In H460 cells, which express
NRP1 but not NRP2, SEMA3F did not prolong survival.
This antitumor effect in H157 cells was associated with
loss of activated AvB3 integrin and adhesion to extra-
cellular matrix components. In addition, H157-SEMA3F
cells, and parental H157 cells exposed to SEMA3F-
conditioned medium, showed loss of p42/p44 MAPK
phosphorylation. Thus, in this in vivo lung cancermodel,
SEMA3F has potent antitumor effects, which may im-
pinge on activated integrin and MAPK signaling.
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Introduction
Semaphorins are a large family of proteins [1] initially
identified by their collapsing activity on growth cones [2,3].
Secreted semaphorins bind high-affinity neuropilin recep-
tors (NRP1 and NRP2) [4,5], which associate with Plexins in
signal transduction [6]. Neuropilins were independently
identified as coreceptors for vascular endothelial growth
factor (VEGF) [7], and the semaphorin/neuropilin system
is an important regulator of cardiovascular development [8].
Two secreted semaphorins, SEMA3B and SEMA3F, are
encoded in 3p21.3, a region that undergoes homozygous
deletion and frequent loss of heterozygosity in lung cancer
[9–11], suggesting that these genes have tumor-suppressor
function. Accordingly, in an in vitro assay, transfection of
SEMA3B into the lung cancer cell line, H1299, led to apoptosis
and reduced colony formation [12]. Tumor-suppressor activity
for SEMA3F was first shown by transfer of an 80-kb genomic
fragment to mouse A9 fibrosarcoma cells [13] and was sub-
sequently confirmed by direct gene transfection [14]. Similarly,
overexpression of SEMA3F by adenovirus in HEK293 cells
was shown to inhibit tumor formation and angiogenesis [15].
Moreover, during submission of our manuscript, Bielenberg
et al. [16] reported that SEMA3F blocked metastases of mela-
noma cells injected subcutaneously into nude mice and that the
tumors were poorly vascularized and encapsulated. In con-
trast, one report [14], using the small cell lung cancer line
GLC45, found no effect on tumorigenicity by SEMA3F, al-
though no other studies have tested the in vivo effects of
SEMA3F in lung cancer cells.
We previously demonstrated that loss of SEMA3F staining
was associated with advanced stage lung cancer and was an
early event in premalignant lesions [17,18]. In vitro, we found
that SEMA3F has a repulsing activity on breast cancer cells
[19]. In addition, exogenous SEMA3F inhibited cell attachment
and spreading, and these effects were counteracted by VEGF
[20]. VEGF has been shown to promote the attachment and
migration of tumor cells in an integrin-dependent manner,
including the activation of avb3 integrin [21]. Interestingly, in
endothelial cells, the secreted semaphorins, SEMA3A (collap-
sin) and SEMA3F, were reported to downregulate activated
avb3 integrin [22], suggesting that similar results might occur
in lung cancer.
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We previously observed that plasmid-mediated SEMA3F
expression led to complete loss of attached cells, and stable
transfectants could not be obtained. In the present study,
using a retroviral vector, we were able to establish stably
transfected derivatives of the non small cell lung cancer cell
lines, NCI-H157 and NCI-H460 (hereafter H157 and H460).
For many tumor lines, subcutaneous injection can be ineffi-
cient, whereas orthotopic administration results in aggres-
sive, metastatic tumors. Therefore, we directly instilled tumor
cells through tracheal intubation into the lungs of nude rats.
In this model system, the antitumor effects of SEMA3F on
the NRP2-expressing H157 cells were dramatic, whereas
H460 cells were not inhibited. Of note, H460 expresses
NRP1, whereas NRP2 expression is barely detectable;
among various semaphorin signaling components, this dif-
ference was the most striking.
In accordance with previously reported effects of VEGF
and SEMA3A on avb3 integrin in melanoma and endothelial
cells, respectively, SEMA3F antitumor activity was asso-
ciated with loss of staining with the WOW-1 antibody, which
binds only activated avb3 integrin. In addition, tumor sup-
pression was associated with downregulation of p42/p44
MAPK phosphorylation.
Materials and Methods
Cell Culture
The lung cancer cell lines NCI-H157 (squamous carci-
noma) and NCI-H460 (large cell carcinoma) were grown in
RPMI 1640 plus 10% fetal calf serum (InVitrogen, Cergy
Pontoise, France). SEMA3F or vector-only expressing cells
were also maintained in 600 mg/ml G418 (InVitrogen). The
packaging cell line PT67 (Clontech, Saint Quentin Fallavier,
France) was similarly grown in DMEM.
Plasmid Constructions
The SEMA3F cDNA was amplified with the following
primers (5V-GC-GAA-TTC-GCC-ACC-ATG-CTT-GTC-GCC-
GGT-CTT-CT-3V) and (5V-GC-GTT-AAC-TCA-CAG-ATC-
CTC-TTC-TGA-GAT-GAG-TTT-TTG-TTC-TGT-GTC-CGG-
AGG-GTG-GTG-CCG-3V), which contains a Myc tag at the
3V end. The fragment was cloned into the EcoRI and HpaI
sites of the pLXSN retroviral vector (Clontech).
Production of SEMA3F Stable Transformants
Stable virus-producing cell lines were generated by trans-
fecting PT67 packaging cells with the SEMA3F-pLXSN con-
struct (or pLXSN vector alone) using Effectene Transfection
Reagent (Qiagen, Courtaboeuf, France) as recommended
by the manufacturer. Cells were selected in 400 mg/ml G418
for 10 days. Virus generated from overnight culture was
used to infect H157 and H460 cells. Single G418–resistant
colonies were isolated in 800 mg/ml G418 for 10 days and
subsequently maintained at 600 mg/ml. DNA was prepared
with the DNeasy Tissue kit (Qiagen) and screened by
PCR using primers 59H8 (5V-TTC-AAC-TTC-CTG-CTC-
AAC-3V) and 39G5 (5V-GAA-GAC-CAT-GCG-AAT-ATC-3V),
as previously described [9]. Southern blot analysis was
performed with the SEMA3F probe at 65jC, using a nylon
membrane (HYBOND-N+; Amersham Pharmacia Biotech,
Orsay, France) in Rapid-hyb buffer (Amersham). Washings
were performed two times for 15 minutes in 0.2 SSC–SDS
0.1% at 65jC.
RNA Expression
Total RNA was extracted using the RNeasy Mini kit
(Qiagen). RT-PCR was performed with Superscript II re-
verse transcriptase (InVitrogen) using the procedure sup-
plied by the manufacturer. We assessed levels of gene
expression relative to GAPDH by quantitative real-time PCR
and the ABI7000 (PE Biosystems, Courtaboeuf, France)
quantitative PCR system with SYBR-Green chemistry. The
PCR was carried out in 20-ml reaction volumes consisting
of 1 PCR SYBR-Green buffer, 0.125 mM primers, 200 mM
of each dNTP, 2 mM MgCl2, and 0.025 U/ml AmpliTaq Gold
(PE Biosystems). The amplification parameters were: 50jC
for 2 minutes, 95jC for 10 minutes, followed by 35 cycles
at 95jC  15 seconds, 60jC  1 minute. Primer sequences
are described in Table 1. The cycle at which a particular
sample reaches an arbitrary fluorescent threshold (Ct) is
proportional to the quantity of the input template.
Western Blot Analysis
A total of 2.5  106 H157 and H460 stably transfected
cells was washed twice with PBS, then lysed in 500 ml of lysis
buffer [1% NP-40 (wt/vol), 1% DOC (wt/vol), 0.1% SDS,
0.15 M NaCl, 0.01 M NaH2PO4, 2 mM EDTA, 0.5 mM PMSF,
10 mg/ml leupeptin, 5 mg/ml pepstatin A, and 1.7 mg/ml
aprotinin] and subsequently sonicated. Total protein was
quantified using the BCA kit (PerBio Sciences, Bezons,
France). Thirty micrograms of protein lysate was resolved
on an 8%SDS-PAGE, followed byWestern blot analysis. Pri-
mary antibodies and dilutions used were: monoclonal anti–
c-MYC (1/2000; Sigma, St. Louis, MO), phospho p42/44
MAPK (1/1000; Cell Signaling, Montigny le Bretonneux,
France), and p42/44 MAPK (1/4000; Promega, Madison,
WI). Secondary antibodies were HRP-labeled (1/5000; PE
Biosystems) and blots were revealed by ECL detection.
Immunofluorescence
For avb3 integrin immunofluorescence, cells were plated
at sparse density on 0.5 mg/ml vitronectin (Chemicon, Souf-
folweyershein, France) and grown for 48 hours. Cells were
fixed and stained with the WOW-1 Fab antibody (kindly
provided by Prof. Sanford Shattil, La Jolla, CA), which selec-
tively recognizes avb3 integrin because of its engineered
RGD segment from the penton-based adenovirus protein
as described [23]. a6 Antibody was from Chemicon (GoH3,
1/50 dilution). The secondary antibodies were antimouse
(for a6) or antirat (for avb3) Alexa 488–conjugated antibody
(1/250 dilution; Molecular Probes, Eugene, OR, USA).
Cell Sedimentation Manifold (CSM) Assays
The CSM (CSM, Inc., Phoenix, AZ) migration assay sys-
tem is composed of 10 aligned channels for sedimentation of
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low cell numbers as discrete circles on Teflon-delineated
wells of slides. Slides were coated with 1% bovine serum
albumin for 1 hour, and 1.5 ml of cells (3  106 cells/ml)
was applied per channel according to the manufacturer’s
protocol. Cells were initially left to sediment for 1 hour at
4jC followed by an additional period of 4 hours at 37jC.
Cells were then maintained for 24 hours at 37jC followed
by photography.
Cell Adhesion
Ninety-six well plates were pretreated with 0.5 mg/ml
fibronectin, vitronectin, or laminin (Sigma-Aldrich, Saint
Quentin Fallavier, France) for 1 hour at 37jC. Uncoated
wells were used as controls. The wells were drained and
nonspecific binding was blocked with PBS/3% BSA for
45 minutes at 37jC then emptied, and 1  103 cells in a
volume of 100 ml were added and left to sediment  1 hour
at 37jC. Unattached cells were aspirated and the attached
cells were fixed (10% formalin  10 minutes at room tem-
perature), stained (0.1% crystal violet  10 minutes at room
temperature), then rinsed three times with distilled water.
Cells were left to dry overnight and counted under a micro-
scope field. Statistical differences were calculated using
the Student’s t test.
Orthotopic Rat Tumor Model
Six- to 8-week–old female athymic nude rats, obtained
from the National Cancer Institute (Washington, DC, USA),
were maintained in pathogen-limited conditions at the Ani-
mal ResourcesCenter, University ofColoradoHealthSciences
Center (Aurora, CO). One day prior to tumor cell installation,
rats (six rats per transformant) were treated with 450 cGy
of total body irradiation using a Co60 source. Control or
SEMA3F-transformed H157 or H460 cells (1  107 cells in
100 ml of serum-free media) were instilled intratracheally into
the left lung of anesthesized rats by administration through
a 3-in. 22-gauge catheter (Popper & Sons, Inc., New Hyde
Park, NY), according to a published procedure [24]. The
procedure required less than 3 minutes and the animals
recovered in less than 5 minutes without showing signs of
stress or casualty. The entire experiment was repeated twice
with essentially identical results. Survival was analyzed using
the Kaplan-Meier survival model and log-rank test. Hazard
ratios for treatment versus control were estimated with 95%
confidence intervals. All statistical analyses were performed
with SAS Software, Version 8.1 (SAS Institute, Cary, NC).
Results
Establishment of H157 and H460 Subclones Stably
Expressing SEMA3F
To study the effect of SEMA3F on in vivo lung tumori-
genicity, we first established stable SEMA3F transfectants
using the squamous carcinoma cell line, H157, and the large
cell carcinoma cell line, H460. These were chosen because
both express low levels of SEMA3F (Table 2). Following
retroviral infection, Myc-tagged SEMA3F-expressing cells
were selected in G418 and analyzed by Southern blot. As
shown in Figure 1A, the intensity of the SEMA3F hybridi-
zation signal indicated that only one copy of SEMA3F had
been integrated. Two independent SEMA3F-expressing
subclones from each tumor cell line (hereafter H157-S1,
H157-S2, H460-S1, and H460-S2) were chosen, as well as
subclones containing only the pLXSN vector (i.e., H157 and
H460-control or CTL). By real-time RT-PCR (Table 2),
SEMA3F mRNA levels were approximately 8- to 16-fold
higher in these various SEMA3F transfectants compared
to either short-term normal bronchial epithelial (NHBE) cul-
tures [18] or normal-appearing bronchial epithelial biopsies
Table 1. Primers Sequences for Real-Time Quantitative RT-PCR.
Forward Reverse
GAPDH 5V-TGC ACC ACC AAC TGC TTA GC-3V 5V-GGC ATG GAC TGT GGT CAT GAG-3V
SEMA3F 5V-AGC AGA CCC AGG ACG TGA G-3V 5V-AAG ACC ATG CGA ATA TCA GCC-3V
PlexA1 5V-TGC AGT GCC AGA ATT CCT CG-3V 5V-TGC GCC TGG ATG TTC TGT G-3V
PlexA2 5V-GTG AGC CTT GCA GTG CAT CC-3V 5V-CCT CCA CCT CTG TCG GGT TC-3V
PlexA3 5V-GTT CCT TGG TGG CAT TGG TG-3V 5V-TTG GTG CCT GTC TCC TGG TC-3V
PlexB1 5V-GAC GTG AGA TAT GCG TCC GTG-3V 5V-CAC GGC TCC TCA AAT TGC TG-3V
PlexB2 5V-TTT CTG GGC ACC TCT GAT GG-3V 5V-GGT CGC GCT TGA CTC TCT TG-3V
CRMP1 5V-ATC GCC AAG GAC TGA CTG AG-3V 5V-GAG GAT GCT TCT CTG CAA CC-3V
CRMP2 5V-TTC TGT CAC CTT TCC CCC TA-3V 5V-AGA GAC AAG GGT GGT GAT GG-3V
CRMP3 5V-CAC CAG GCT TCT TGG TGA AC-3V 5V-GGT CCC TGA AGT CTC AGC AG-3V
CRMP4 5V-GGA AAG GGT GTT TGG GAA AT-3V 5V-AAT CCA GGC TCA GGT GTC AG-3V
VEGF 5V-CAA GAC AAG AAA ATC CCT GTG G-3V 5V-CCT CGG CTT GTC ACA TCT G-3V
VEGFR1 5V-ATG CCA CCT CCA TGT TTG ATG-3V 5V-GAG GCC TTG GGT TTG CTG TC-3V
VEGFR2 5V-TTC TCT TGA TCT GCC CAG GC-3V 5V-AGG CTC CAG TGT CAT TTC CG-3V
NRP1 5V-ATC ACG TGC AGC TCA AGT GG-3V 5V-TCA TGC AGT GGG CAG AGT TC-3V
NRP2 5V-GGA TGG CAT TCC ACA TGT TG-3V 5V-ACC AGG TAG TAA CGC GCA GAG-3V
Int a5 5V-TGT CAC CAT CCT TAA TGG CTC A-3V 5V-GGC CAC TGC ATA GCC AAA GTA G-3V
Int av 5V-GAA CGC AGT CCC ATC TCA AAT C-3V 5V-GGC TCC TTT CAT TGA ATA GCC A-3V
Int a6 5V-CCT TTG ACA CCC CAT ATC TGG A-3V 5V-CGA GAC CGA TAA AAG CAG TTC A-3V
Int b1 5V-TGC CGG GTT TCA CTT TGC-3V 5V-GTG ACA TTG TCC ATC ATT TGG TAA A-3V
Int b3 5V-TGA CCC GCT TCA ATG AGG AA-3V 5V-CCT CCA GCC AAT CTT TTC ATC A-3V
Int b4 5V-GAG GAT GAC GAC TGC ACC TAC A-3V 5V-GGC AGT CCT TCT TCT TGT GCA C-3V
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(unpublished observations). Compared to NHBE cells, the
normal lung expresses higher levels of SEMA3F (i.e., four-
fold to five-fold greater), which we suspect is due to the
endothelial component based on expression results in
HUVEC cells (unpublished observations). Thus, the retro-
viral infections resulted in overexpression of SEMA3F, albeit
at levels that were tolerated by the recipient cells. Also, levels
of exogenous SEMA3F mRNA were comparable in the H157
and H460 transfectants (Table 2).
SEMA3F protein expression was verified by Western blot
analysis (Figure 1B). A band of the expected size (f80 kDa)
was detected using the anti-Myc antibody specifically in
transfected cells. In H460-S1, however, a doublet was ob-
served, the nature of which is unknown. The intensity of the
observed bands reflected the amount of SEMA3F mRNA. As
expected for a secreted protein, strong immunofluorescence
staining was concentrated in the Golgi region ( H157-S1 in
Figure 1C, parts b and c).
SEMA3F Inhibits Tumorigenicity of H157 Cells But
Not H460
SEMA3F-expressing H157 and H460 cells, plus controls,
were injected into the left lung of nude rats through tracheal
administration. In two independent experiments, all animals
receiving H157 control cells died with a median survival of
52 days, whereas no animal receiving SEMA3F-expressing
cells (H157-S1 and H157-S2) had died by 100 days (P < .001;
see Figure 2A). Lungs isolated from control animals showed
massive primary tumors with multiple metastases in the right
lung and mediastinal lymph nodes. In a few H157-S1– and
H157-S2–injected rats followed to day 220, only small pri-
mary tumors were observed in the left lung. These were
not analyzed for loss of SEMA3F. In contrast, exogenous
expression of SEMA3F in H460 cells had no effect on the rat
survival compared to controls (Figure 2B).
With these results, we looked for differences in compo-
nents of the class 3 semaphorin signaling pathway (NRPs,
Plexins, and CRMP) VEGF and VEGF receptors (VEGFR1
and VEGFR2) using quantitative RT-PCR (Table 2). Al-
though some clonal variations were observed, these results
demonstrated that H157- and H460-transfected cells ex-
pressed comparable levels of Plexin A1, Plexin A3, Plexin
B1, and Plexin B2. Plexin A2 was not expressed in H157,
whereas it was moderately expressed in H460. Although
considerable complexity in Plexin–NRP interactions prob-
ably exists, the absence of Plexin A2 in H157 cells would
be an unlikely explanation for the observed differential tumor
suppression. CRMP1 expression was three-fold higher in
H157 cells, although the pattern was reversed for CRMP4.
VEGF levels were considerably higher (23-fold) in the
SEMA3F-sensitive (H157) cells, whereas VEGFR1 and
VEGFR2 were not, or only slightly, expressed in either cell
line. In contrast to these results, the major observed dif-
ference involved NRP2, which was essentially absent in
H460. In addition, NRP1, the lower-affinity receptor, was
expressed at nine-fold higher levels in H157 cells. Thus,
we suspect that SEMA3F receptor levels may explain the
observed differential antitumor responsiveness.
Table 2. RNA Expression of Selected Genes in H157 and H460 Trans-
fectants and Controls.
H157 CTL H157-S1 H157-S2 H460 CTL H460-S1 H460-S2
SEMA3F 0.07 26.79 93.30 0.01 53.59 50.00
PlexA1 0.30 0.17 0.18 0.12 0.09 0.20
PlexA2 0.00 0.00 0.00 0.09 0.17 0.21
PlexA3 4.12 3.35 2.54 1.79 1.67 1.92
PlexB1 0.21 0.21 0.22 0.17 0.15 0.18
PlexB2 2.92 2.92 5.08 1.79 2.21 3.85
CRMP1 0.28 0.24 0.39 0.09 0.05 0.07
CRMP2 5.44 5.44 7.69 7.18 3.35 5.83
CRMP3 0.00 0.00 0.00 0.00 0.00 0.00
CRMP4 0.01 0.12 0.00 1.18 0.17 0.21
VEGF 4.42 1.92 2.06 0.20 0.20 0.22
VEGFR1 0.00 0.00 0.00 0.00 0.00 0.00
VEGFR2 0.00 0.01 0.01 0.00 0.00 0.00
NRP1 1.56 0.78 2.06 0.17 0.28 0.34
NRP2 0.73 0.59 0.68 0.00 0.00 0.00
Int a5 3.35 3.35 1.92 0.32 0.20 0.21
Int av 9.47 9.47 9.47 2.37 0.90 0.90
Int a6 3.59 1.46 3.35 0.42 0.45 0.39
Int b1 1.79 4.12 2.92 1.27 1.67 0.96
Int b3 3.13 8.84 6.70 0.00 0.01 0.01
Int b4 0.12 0.21 0.28 0.01 0.00 0.00
RNA expression was estimated by real-time quantitative PCR and expressed
as percentage of GAPDH expression. CTL is control clones (vector-only
transfected cells).
Figure 1. Establishment of H157 and H460 clones stably expressing
SEMA3F. Southern blot (A) was performed with the SEMA3F cDNA probe
and HpaI and EcoRI digested DNA from SEMA3F transformants and control
(vector only) cells. DNA markers are indicated in kilobasepairs on the left. The
arrow indicates the transfected SEMA3F DNA; the upper band is the endo-
genous SEMA3F. DNA from the Glc20 cell line was chosen as a negative
control as these cells are homozygously deleted for SEMA3F [43]. SEMA3F
protein was detected on the S1 and S2 subclones with an anti-Myc antibody
by Western blot analysis (B) and immunofluorescence (C). The arrow in-
dicates the SEMA3F band; protein markers are indicated in kilodaltons (B).
(c) An enlargement of (b) Only background was detected by immuno-
fluorescence in H157-CTL (a) Scale bar, 50 m.
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Changes in Cell Morphology and Downregulation
of Activated av3 Integrin by SEMA3F
Compared to controls, H157 cells transfected with
SEMA3F appeared more rounded when plated on culture
dishes (Figure 3A). This involved loss of protrusions and
large lamellipods. A few hours after plating, this effect was
lessened and no difference was observed with confluent
cells. We used a cell sedimentation device (CSM, Inc.) to
examine cell migration. Concentrated cells were deposited
onto a circular area of a coated microscope slide and
examined after 24 hours. At the periphery, H157-S1 cells
were isolated whereas control cells retained close inter-
cellular contacts (Figure 3B).
Recently, SEMA3A and SEMA3F were shown to anta-
gonize VEGF-induced integrin activation in endothelial
cells [22]. Because integrins contribute to signaling from var-
ious tyrosine kinase receptors and contribute as well to tu-
morigenesis, metastasis, and angiogenesis (for review, see
Ref. [25]), we looked for effects of integrin activation in
SEMA3F-transfected cells. For this purpose, we used the
recombinant antibodyWOW-1, which specifically recognizes
the active form of avb3 integrin [23]. H157 and H460 cells
were plated on vitronectin (the major substrate for avb3
integrin) and avb3 integrin activation was followed by immu-
nofluorescence. Although H460 cells did not express avb3
integrin at the RNA level (Table 2), activated avb3 integrin
membrane staining was detected in H157 control cells
(Figure 4A), whereas this staining was abolished in the
SEMA3F transfectants. This effect was specific, as neither
the expression nor localization of total a6 integrin subunit was
affected (Figure 4B). Analysis of various integrins by RT-
PCR (Table 2) demonstrated that most family members were
expressed at much lower levels in H460 cells. Only b1
integrin was comparably expressed at the mRNA level.
Unfortunately, we did not have antibodies directed against
the activated form of b1 integrin.
To pursue this observation, we performed adhesion tests
on plastic, fibronectin, vitronectin, and laminin substrates.
Adhesion on each substrate is integrin-dependent, although
different a–b subunits (e.g., avb3 and a5b1) are involved.
More control H157 cells attached to fibronectin and vitro-
nectin than to plastic or laminin in serum-free medium dem-
onstrating substrate-specific adhesion (Figure 5). With
conditioned medium (containing serum) from H157 control
cells, adhesion to all substrates was enhanced. In contrast,
when the conditioned media from the control cells were
replaced by medium from H157-S1 or H157-S2 cells, adhe-
sion to fibronectin and vitronectin was significantly reduced
(Figure 5) (for H157 cells treated by H157-S1 and -S2
conditioned media, P values for adhesion on fibronectin
are .04385 and .03877, respectively and, for adhesion on
vitronectin, P values are .0031 and .01802 respectively).
Thus, we suggest that SEMA3F downregulates the active
form of avb3 integrin in H157 cells. In contrast, conditioned
media from the SEMA3F-expressing H460 clones had no
Figure 2. SEMA3F inhibits tumorigenicity of H157 cells but not H460. Sur-
vival curves are presented for rats injected into the lung with SEMA3F trans-
fectants or control H157 (A) and H460 (B) cells.
Figure 3. Changes in cell morphology of SEMA3F-transfected H157 cells.
Cell morphology was observed for H157 control and SEMA3F-transfected
cells (A) several hours after plating. Cells were also observed at time
24 hours, at the periphery of an island of concentrated cells obtained with the
CSM device (B). Scale bar, 100 m.
Anti-Tumor Activity of SEMA3F Kusy et al. 461
Neoplasia . Vol. 7, No. 5, 2005
effect on the adherence of H460 cells to the various sub-
strates (data not shown).
Downregulation of Phospho-MAPK and Cell Proliferation
by SEMA3F
In neurons, movement of growth cones away from a
SEMA3A source involves changes in MAPK phosphoryla-
tion [26,27]. Therefore, we examined phosphorylation of
p42/p44 MAPK in the SEMA3F transfectants. As shown in
Figure 6A, H157-S1 and S2 cells were found to have re-
duced levels of phospho-p42/p44 MAPK compared to con-
trols. To exclude the possibility that this was due to clonal
variation, we treated H157 parental cells with cultured super-
natants from either control or H157-S1 cells. As shown in
Figure 6B, phospho p42/p44 MAPK was downregulated by
conditionedmedia fromH157-S1 but not control cells. In con-
trast, the endogenous low level of phospho-p42/p44 MAPK
in H460 cells was either unchanged or even increased in
the SEMA3F-expressing clones (Figure 6A). The observed
increase in H460-S1 MAPK phosphorylation was likely due
to clonal variation because, when added to the parental
cells, SEMA3F-containing media had no effect on p42/44
MAPK phosphorylation (Figure 6B).
Discussion
The role of secreted class 3 semaphorins (which includes
SEMA3F [1]) as tumor-suppressor proteins has emerged
during the last few years. SEMA3F was identified by posi-
tional cloning of genes from a homozygous 3p21.3 deletion
identified in lung cancer cell lines. Although SEMA3F has
activities consistent with tumor-suppressor function in vitro
[12], there has been no report demonstrating in vivo activ-
ity in lung cancer. The results described above, using an
orthotopic model of lung cancer with H157 cells, clearly
establish that SEMA3F has potent antitumor function and
provide clues as to the involved mechanisms. To our
knowledge, this is the first in vivo evidence of such activity
in lung cancer.
These results are in agreement with two previous reports
demonstrating that SEMA3F inhibited subcutaneous tumors
formed by either mouse A9 fibrosarcoma cells, HEY ovarian
Figure 4. Downregulation of activated av3 integrin by SEMA3F. Immunocytochemistry was performed on H157 and H460 control and SEMA3F-transfected cells
with WOW-1, an anti –activated av3 integrin antibody (A), or an anti –a6 integrin antibody (B). H157 cells were stained with DAPI (A). No change in staining was
noticed with the anti –a6 integrin, whereas loss of av3 staining was observed for H157-S1 and H157-S2. Scale bar, 50 m.
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carcinoma, or HEK293 cells in nude mice [14,15]. However,
whereas these latter studies demonstrated an antitumor
activity of SEMA3F, the importance of SEMA3F loss has
not been defined in either rodent sarcomas, human ovarian
cancer, or HEK293 cells (which were derived from normal
embryonic kidney). Moreover, it has been our experience
that lung cancer cell lines are considerably more tumorigenic
when administered orthotopically compared to subcuta-
neous injections. Nevertheless, taken together, these results
are consistent and strongly support the role of SEMA3F as
a tumor-suppressor gene.
In contrast to H157, SEMA3F-transfected H460 cells
readily formed tumors. Indeed, in other model systems,
SEMA3F tumor inhibition was specific; no activity was found
in the small cell lung carcinoma cell line, GLC45 [14].
Moreover, SEMA3F had reduced in vitro antitumor activity
compared to SEMA3B in H1299 lung cancer cells [12]. One
simple explanation for these results could be the absence
of NRP2—the highest affinity SEMA3F receptor. However,
NRP2 was expressed in GLC45 [14], although the levels
were not provided. In the present study, we looked for dif-
ferences that might explain the SEMA3F sensitivity of H157
cells compared to H460. We found that variations in levels
of VEGF, VEGF receptors, and downstream NRP signaling
components (i.e., Plexin and CRMP family members) ap-
peared to be insufficient to explain the observed biologic
effects. In contrast, the major difference was NRP2, which is
essentially absent in H460. However, formal proof will re-
quire exogenous NRP2 expression in this cell line. Moreover,
we cannot exclude the difference in aggressiveness of these
two cell lines.
Visually, SEMA3F-expressing H157 cells showed sub-
stantial changes not observed in H460. H157 cells lost la-
mellipods and were rounded, effects that appeared identical
to those in the breast cancer cell lines, MCF7 and C100 [20],
as well as in endothelial cells treated with exogenous
SEMA3F [15]. This ‘‘collapsing activity’’ has also been dem-
onstrated for SEMA3A in COS7 cells [28], as well as for
COS7, 3T3, and SKBR3 cells treated with SEMA4D [29].
Moreover, with the CSM device, we observed that SEMA3F-
transfected H157 cells showed reduced intercellular contacts
at the periphery of the islet. We and others have previously
shown that secreted semaphorins negatively affect adhesion
and migration of tumor cell lines, and that exogenous VEGF
can block these effects [19,20,30–32]. Strikingly, it was
recently reported that SEMA3F inhibits VEGF-induced avb3
and a5b1 integrin activation in endothelial cells [22]. These
findings are in agreement with the report of Byzova et al. [21]
demonstrating that VEGF enhances tumor cell adhesion and
migration in an integrin-dependent manner with avb3 integrin
being one of the important components.
In SEMA3F-transfected H157 cells, we found loss of
activated avb3 integrin staining. These results were substan-
tiated with the demonstration of reduced adhesion to fibro-
nectin and vitronectin. During submission of our manuscript,
similar results were reported using another system: inhi-
bition of metastasis and integrin function with SEMA3F-
overexpressing melanoma cells in nude mice [16]. Integrins
mediate cellular adhesion and migration on extracellular
matrix (ECM) components [25,33–35]. They also regulate
cell cycle entry, and withdrawal, apoptosis, and metastasis.
For instance, strategies that inhibit the av subunit result in
loss of melanoma tumorigenicity, activation of p53, and
blocking of Bcl-2 expression [36–39]. Furthermore, avb3
integrin binds MMP-2 and facilitates matrix degradation
and invasion [40]. avb3 Integrin plays a very important role
in cancer through angiogenesis. It regulates vascular cell
Figure 5. SEMA3F reduced the adhesion of H157 control cells to fibronectin
and vitronectin. H157 control (CTL) cells were grown on different substrates:
plastic (PL), fibronectin (F), vitronectin (V), and laminin (L) with a serum-free
medium (+0) or control (+CTL), S1 (+S1), or S2 (+S2) conditioned media. The
number of attached cells on each substrate is expressed as the mean number
of cells. Assays were done in triplicate for two independent experiments.
*P value < .05.
Figure 6. Downregulation of MAPK phosphorylation by SEMA3F. Western
blot analysis of protein extracts of H157 and H460 control and SEMA3F-
transfected cells with anti –p42/44 MAPK and anti –phosphorylated p42/44
MAPK antibodies (A). Parental cells were treated either with control or S1-
conditioned media for 6 hours (B), and Western blot analysis was performed
as in (A).
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survival in vivo, and avb3 antagonists disrupt angiogenesis
and induce tumor regression (see review in Ref. [25]). Thus,
the observed loss of activated avb3 integrin staining (in H157
cells) in response to SEMA3F is likely to be an important
mechanism of its antitumor activity.
Because semaphorins affect MAPK activity [15,26,
27,41], we examined the phosphorylation of p42/p44
MAPK in transfected cells. Signaling through MAPK repre-
sents a critical focal point in the response of multiple recep-
tors involved in tumorigenesis [42]. Importantly, the H157
SEMA3F transfectants had reduced levels of phopho-p42/
p44 MAPK and the same was true when H157 parental cells
were exposed to conditioned medium from the SEMA3F
transfectants, excluding clonal variation as an explanation.
In neurons, the opposite effect was reported for SEMA3A
[26], and repulsion of neuronal progenitors, as well as protein
synthesis regulation, involve the activation of p42/p44 MAPK
[27,41]. However, in HUVEC cells, SEMA3F has been
shown to inhibit VEGF as well as bFGF-induced p42/p44
MAPK phosphorylation [15]. Thus, semaphorin effects on
MAPK phosphorylation show cell type specificity, probably
reflecting the complexity of growth factor signaling and cell
extracellular matrix interactions.
In summary, we have described the tumor-suppressor
activity of SEMA3F in H157 lung cancer cells in an in vivo
model. We suggest that this activity is mediated by reduc-
tions in activated integrins and MAPK signaling in this cell
line. In the presence of normal levels of SEMA3F, the
propensity of developing lung cancer cells to interact with
the stroma might be diminished. This is in agreement with
our previous studies demonstrating that SEMA3F loss oc-
curred early during human lung tumorigenicity [18] and was
also associated with more aggressive lung tumors [17].
Recent published data [14–16], together with the results
presented here, strongly support the role of SEMA3F as a
tumor-suppressor gene in diverse cell types, and raise the
possibility that pharmacologic approaches to reexpress
SEMA3F have therapeutic potentials.
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